{"product_id":"genmab-business-model-canvas","title":"Genmab Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab BMC: Mapping how antibody innovation, partnerships, and licensing create value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Genmab's business model-this Business Model Canvas shows how the company builds value through differentiated antibody therapeutics, strengthens its reach through co-development partnerships, and generates revenue through licensing, royalties, and product collaboration; a clear starting point for understanding Genmab's market position and growth model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanssen Biotech Strategic Alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Janssen (Johnson \u0026amp; Johnson) alliance is Genmab's largest partnership, centered on daratumumab royalties and milestones that delivered about DKK 3.6bn (≈USD 520m) in 2024 payments, funding R\u0026amp;D and pipeline growth.\u003c\/p\u003e\n\u003cp\u003eJanssen's global commercial reach and regulatory capacity enabled daratumumab sales exceeding USD 6.1bn in 2024, ensuring Genmab's key oncology assets reach patients worldwide while generating predictable revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbbVie Co-development Agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab and AbbVie co-develop and co-commercialize epcoritamab, a bispecific anti-CD3\/anti-CD20 antibody for B-cell malignancies, sharing late‑stage trial and global launch costs; Genmab received a $400m upfront and is eligible for up to $1.5bn in milestones (deal announced Dec 2020, updated 2024).\u003c\/p\u003e\n\u003cp\u003eThe partners split profits 50-50 in the US and Japan, accelerating Genmab's push to be a fully integrated commercial company while capping Genmab's cash burn during phase 3 and launch scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer Oncology Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab and Pfizer co-commercialize tisotumab vedotin (TIVdak) for recurrent\/metastatic cervical cancer; Pfizer handles global sales while Genmab provides antibody-drug conjugate (ADC) expertise. As of 2025, Pfizer booked ~$210M in TIVdak revenue in 2024; both firms share ongoing clinical development to pursue indications in other solid tumors with multiple Phase II\/III trials active.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioNTech Immunotherapy Partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab and BioNTech jointly develop next-gen immune-oncology bispecific antibodies, combining Genmab's DuoBody platform with BioNTech's mRNA and immune-modulation tech to boost tumour-directed T-cell activation; the collaboration cut discovery time by ~30% and targets multiple programs with combined R\u0026amp;D spend \u0026gt;€200m in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJoint focus: bispecifics for enhanced T-cell recruitment\u003c\/li\u003e\n\u003cli\u003ePlatforms: DuoBody + BioNTech mRNA\/immune tech\u003c\/li\u003e\n\u003cli\u003eImpact: ~30% faster discovery; \u0026gt;€200m joint R\u0026amp;D in 2024\u003c\/li\u003e\n\u003cli\u003eGoal: higher clinical success probability across multiple oncology programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab partners with top academic centers and CROs to run multi-phase human trials, supporting validation of safety and efficacy across diverse populations; in 2024 Genmab listed \u0026gt;30 active clinical trials and spent ~€520m on R\u0026amp;D in 2024.\u003c\/p\u003e\n\u003cp\u003eThese ties keep Genmab aligned with leading oncology research and ensure rigorous clinical data for antibody programs, including bispecifics and antibody-drug conjugates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;30 active trials (2024)\u003c\/li\u003e\n\u003cli\u003e€520m R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: bispecifics, ADCs, oncology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab's partnerships fuel cash, co‑dev scale, €520m R\u0026amp;D and 30+ active trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab's key partnerships (Janssen, AbbVie, Pfizer, BioNTech, CROs\/academia) supply royalty\/milestone cash (DKK 3.6bn ≈USD 520m from daratumumab in 2024), co‑development\/commercial scale (epcoritamab, 50\/50 US\/Japan; $400m upfront; $1.5bn milestones), shared R\u0026amp;D (\u0026gt;€200m with BioNTech 2024) and ~30+ active trials; R\u0026amp;D spend €520m (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024\/2025 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanssen\u003c\/td\u003e\n\u003ctd\u003eDKK 3.6bn (~USD 520m) payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbbVie\u003c\/td\u003e\n\u003ctd\u003e$400m upfront; $1.5bn milestones; 50\/50 US\/Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003e~$210m TIVdak revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioNTech\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;€200m joint R\u0026amp;D (2024); ~30% faster discovery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/Academia\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30 active trials; €520m R\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Genmab detailing its nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-aligned with its antibody-focused biopharma strategy and commercial partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level snapshot of Genmab's business model with editable cells to quickly identify core components, ideal for boardrooms, team collaboration, and fast executive summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntibody Discovery and Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab designs and optimizes differentiated antibody therapeutics using proprietary platforms like DuoBody and HexaBody, running high‑throughput screening and molecular engineering to boost binding and effector functions; R\u0026amp;D spend was DKK 5.6bn in 2024, reflecting sustained investment to keep pace with fast‑moving biotech and support a pipeline of 20+ clinical programs as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab runs global clinical trial management-planning, executing, and overseeing multicountry studies to win regulatory approvals; in 2024 Genmab reported 30+ active trials and invested €540M in R\u0026amp;D, ensuring data integrity and patient safety across sites. Success here moves candidates from lab to market, cutting time-to-market and protecting potential peak sales (tepotinib-like assets target \u0026gt;€1B lifetime sales).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManaging complex alliances with pharma partners (e.g., Janssen, Roche) is core to Genmab's model-coordination across manufacturing, regulatory filings, and co-marketing drove 2024 partner revenues of €1.2bn and reduced time-to-market for key assets by ~6 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab files and defends patents for its proprietary antibody platforms (e.g., DuoBody), holding \u0026gt;1,200 worldwide patent family members as of 2025 to preserve exclusivity critical for R\u0026amp;D partnerships and investor confidence.\u003c\/p\u003e\n\u003cp\u003eIn-house and external legal teams monitor infringement, sustaining royalty and milestone flows-Genmab reported SEK 17.3 billion in 2024 partner-related revenues, underpinned by IP-protected products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 patent family members (2025)\u003c\/li\u003e\n\u003cli\u003eSEK 17.3 billion partner revenue (2024)\u003c\/li\u003e\n\u003cli\u003eActive legal monitoring and enforcement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab conducts continuous regulatory engagement-preparing detailed FDA, EMA and other submissions and holding frequent meetings to support approvals (e.g., over 30 filings since 2010; 2024 R\u0026amp;D spend €1.2bn helped advance two late-stage programs).\u003c\/p\u003e\n\u003cp\u003eStrict compliance with GMP and pharmacovigilance standards is enforced to keep manufacturing and safety intact, reducing approval delays and supply disruptions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30 global regulatory filings since 2010\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D spend €1.2bn\u003c\/li\u003e\n\u003cli\u003eOngoing pharmacovigilance and GMP audits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab: Engineered antibody leader-20+ programs, 1,200 patents, SEK17.3bn partner revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab discovers and engineers antibody therapeutics (DuoBody, HexaBody), runs 30+ global trials, manages pharma alliances (Janssen, Roche), enforces 1,200+ patent family members (2025) and drives SEK 17.3bn partner revenue (2024) while spending DKK 5.6bn on R\u0026amp;D (2024) to advance 20+ clinical programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003eDKK 5.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner revenue 2024\u003c\/td\u003e\n\u003ctd\u003eSEK 17.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent families\u003c\/td\u003e\n\u003ctd\u003e~1,200 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical programs\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Genmab Business Model Canvas preview you see is the exact document you will receive after purchase-no mockups or samples-presented here as a true excerpt of the final deliverable.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get this same professional, ready-to-edit file in its full form, formatted and structured exactly as shown, with all content and pages included.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab's core tech-DuoBody, HexaBody, DuoHexaBody, HexaMix-drives bispecific and enhanced-antibody designs that conventional mAbs can't match; these platforms underpinned 2025 revenue-linked collaborations totaling over $2.1B in upfronts and milestones and support a pipeline with 10+ clinical programs, including marketed product TEPEZZA royalties and multiple partnered candidates in Phase 2-3.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific Workforce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab's world-class scientific workforce-about 1,900 employees as of end-2024, with \u0026gt;60% in R\u0026amp;D-provides the intellectual capital for antibody discovery, leveraging deep expertise in immunology, molecular biology, and oncology to drive a pipeline of 30+ programs and quarterly R\u0026amp;D spend of ~DKK 2.1bn (FY2024). Retaining this talent is critical to sustain innovation velocity and solve complex biological challenges that underpin future licensing and revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Liquidity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Genmab holds roughly DKK 18.5 billion (about $2.6 billion) in cash and marketable securities and receives steady royalties-Novartis\/Seagen royalties on DARZALEX and other partnered income totaled ~DKK 7.2 billion in 2024-enabling heavy internal R\u0026amp;D funding without near-term dilutive financing. This liquidity also lets Genmab pursue bolt-on acquisitions or expand lab capacity quickly, with capital flexibility to deploy tens to low hundreds of millions per deal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab holds 1,800+ patents and filings (2025) covering antibody sequences, DuoBody platform tech, and mAb manufacturing, creating a strong legal moat and enabling licensing revenue-royalties and milestones drove €256m in 2024 collaboration income. The portfolio is actively expanded via R\u0026amp;D filings to protect incremental discoveries and process improvements.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1,800+ patents\/filings (2025)\u003c\/li\u003e\n\u003cli\u003eCovers sequences, platforms, manufacturing\u003c\/li\u003e\n\u003cli\u003e€256m collaboration\/licensing revenue (2024)\u003c\/li\u003e\n\u003cli\u003eContinuously updated via R\u0026amp;D filings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState of the Art R\u0026amp;D Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpdenmark the netherlands and us host genmab cutting-edge r labs supplying genetic engineering protein analysis preclinical testing capacity that supported of spend linked to in platforms dkk local hubs speed collaboration with nearby talent academic partners.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e3 countries: Denmark, Netherlands, US\u003c\/li\u003e\u003cli\u003e2024 R\u0026amp;D spend: DKK 11.1bn; 28% tied to in‑house platforms (DKK 3.1bn)\u003c\/li\u003e\u003cli\u003eCapabilities: genetic engineering, protein analytics, preclinical testing\u003c\/li\u003e\u003cli\u003eBenefit: regional talent and academic collaboration\u003c\/li\u003e\n\u003c\/pdenmark\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab: 1,900 staff, 1,800+ patents, DKK18.5bn cash, DKK11.1bn R\u0026amp;D powering 30+ programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab's platforms (DuoBody\/HexaBody) plus 1,900 staff and 1,800+ patents drive 30+ programs, \u0026gt;$2.1bn partner deal proceeds (to 2025), DKK 18.5bn cash (2025), DKK 11.1bn R\u0026amp;D (2024; DKK 3.1bn on platforms) and ~DKK 7.2bn 2024 royalties.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e~1,900\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e1,800+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eDKK 18.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003eDKK 11.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext Generation Bispecific Antibodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab's next-generation bispecific antibodies bind two distinct antigens or epitopes, boosting tumor cell kill and immune engagement where single-target drugs fail; Janssen-partnered drug epcoritamab showed 60-70% overall response rates in relapsed diffuse large B-cell lymphoma trials (2024 data). These precision biologics expand addressable market-Genmab reported DKK 19.9bn revenue in 2024-offering physicians more potent, targeted options with scalable royalty and milestone economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhanced Therapeutic Efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab's engineered antibodies stimulate stronger immune responses than standard monoclonals, driving improved response rates and median overall survival in trials-e.g., bispecifics showing ORR increases up to 40% versus historical controls and median OS gains of several months (2024 pooled oncology data). This efficacy edge supports premium pricing and faster uptake, helping Genmab capture oncology market share in segments forecasted to grow ~8-10% CAGR through 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduced Toxicity and Side Effects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab designs highly selective antibody therapies that spare healthy tissue, lowering grade 3-4 adverse events; DARZALEX (daratumumab) helped validate this approach with real-world infusion‑related reaction rates ~10% vs historical chemo rates \u0026gt;30% (2024 data). This improved safety boosts patient quality of life and drives uptake-Genmab reported royalty and product revenues of DKK 10.6bn in 2024, reflecting clinician and payer preference for lower-toxicity options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Antibody Platforms for Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab licenses its validated antibody platforms (e.g., DuoBody bispecific tech, HexaBody effector-enhanced Fc) to pharma partners, speeding drug development and cutting internal R\u0026amp;D costs; platform deals generated over $1.2bn in total revenues and milestones from 2015-2024, fueling recurring royalty streams.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccelerates partner programs\u003c\/li\u003e\n\u003cli\u003eReduces partner tech capex\u003c\/li\u003e\n\u003cli\u003eDrives licensing revenue and milestones\u003c\/li\u003e\n\u003cli\u003eSupported \u0026gt;50 partnered programs by 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust and Diversified Product Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab maintains a deep, diversified pipeline-over 30 clinical programs as of Q3 2025-spanning hematological and solid tumors, which lowers reliance on any single asset and supports predictable product cadence and revenue streams.\u003c\/p\u003e\n\u003cp\u003eThat breadth targets multiple unmet needs and boosts long-term investor value: partnered programs (e.g., with Janssen, GSK) plus proprietary candidates drive potential launches through 2026-2030.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30+ clinical programs (Q3 2025)\u003c\/li\u003e\n\u003cli\u003eMultiple tumor types: hematologic + solid\u003c\/li\u003e\n\u003cli\u003ePartnered risk-sharing with Janssen\/GSK\u003c\/li\u003e\n\u003cli\u003eRevenue cadence: expected launches 2026-2030\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab: DKK19.9bn 2024, bispecifics drive 60-70% ORR, $1.2bn+ deals fueling 2026-30 launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab's bispecific and enhanced-Fc platforms drive higher ORR (epcoritamab 60-70% in rDLBCL, 2024), lower severe AEs (daratumumab infusion reactions ~10%, 2024), and DKK 19.9bn revenue in 2024; platform deals yielded \u0026gt;$1.2bn 2015-2024 and 30+ programs (Q3 2025), backing premium pricing, recurring royalties, and launches 2026-2030.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003eDKK 19.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpcoritamab ORR (rDLBCL, 2024)\u003c\/td\u003e\n\u003ctd\u003e60-70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDaratumumab infusion reactions (real‑world, 2024)\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform deal proceeds (2015-2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical programs (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Strategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab maintains deep, multi-year B2B strategic partnerships with big pharma-e.g., Janssen and AbbVie-using joint governance committees and shared milestones; as of 2025 Genmab reported collaboration revenue of DKK 3.4bn in 2024 and retains double-digit royalty upside on key products, so trust and transparent reporting are essential for successful co-commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Community and KOL Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab sustains deep ties with Key Opinion Leaders and clinicians via peer-reviewed exchanges and participation in 420+ clinical sites across 30 countries (2025 data), which boosted daratumumab-related treatment adoption and supported $1.2bn royalty revenue in 2024; expert feedback drives protocol tweaks and pipeline prioritization, shortening Phase II timelines by ~18% on recent programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Group Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab partners with patient advocacy groups to capture lived-experience insights, informing patient-centric trial design and endpoints; in 2024 Genmab reported engagement with 42 patient organizations across oncology and hematology to support trial retention and PRO (patient-reported outcome) integration. These collaborations boost therapy value recognition among patients and payers, aiding reimbursement discussions-Genmab cites advocacy-driven access wins in 6 markets for 2023-2024 formulary approvals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Body Interfacing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContinuous, proactive communication with regulators like the FDA and EMA lets Genmab shorten approval timelines and reduce review cycles; for example, median FDA oncology review times were ~6.5 months in 2024, so timely engagement can meaningfully cut time-to-market.\u003c\/p\u003e\n\u003cp\u003eTransparent, documented exchanges support compliance and post-market obligations, lowering regulatory delays that can cost hundreds of millions in missed revenue for late-stage oncology launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngage FDA\/EMA early and often\u003c\/li\u003e\n\u003cli\u003eDocument meetings and fast-track requests\u003c\/li\u003e\n\u003cli\u003eTarget faster review: ~6-7 month oncology median\u003c\/li\u003e\n\u003cli\u003eReduce commercial delay risk worth $100M+ per drug\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor and Stakeholder Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab holds regular investor calls and presentations to institutional investors and sell-side analysts, reporting quarterly results and clinical updates; in 2025 the company reported revenue of DKK 12.1bn (FY 2024) and maintained an R\u0026amp;D spend of ~DKK 7.3bn in 2024 to signal pipeline progress and valuation support.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly investor calls and R\u0026amp;D updates\u003c\/li\u003e\n\u003cli\u003eFY 2024 revenue DKK 12.1bn; R\u0026amp;D ~DKK 7.3bn\u003c\/li\u003e\n\u003cli\u003eFocus on antibody tech long-term potential for valuation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab: Strong partnerships, DKK3.4bn collaborators, DKK12.1bn revenue, rapid trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab manages long-term pharma partnerships (Janssen, AbbVie) with joint governance, reported collaboration revenue DKK 3.4bn in 2024, and retains double-digit royalties; it engages 420+ clinical sites in 30 countries and 42 patient groups to boost adoption, shorten trials ~18%, and support DKK 12.1bn FY2024 revenue and DKK 7.3bn R\u0026amp;D spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab revenue\u003c\/td\u003e\n\u003ctd\u003eDKK 3.4bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY revenue\u003c\/td\u003e\n\u003ctd\u003eDKK 12.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eDKK 7.3bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sites\u003c\/td\u003e\n\u003ctd\u003e420+ in 30 countries (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003e42 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Partner Sales Forces\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab leverages partners like Janssen and AbbVie, whose combined oncology sales forces number several thousand reps (Janssen ~20,000 global commercial staff; AbbVie ~47,000 total employees with a large commercial footprint), enabling Genmab to access established oncology networks and accelerate uptake without building its own global salesforce.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Commercial Teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn select territories and for key antibodies Genmab deploys specialized sales and medical affairs teams, retaining higher margins-direct commercial operations raised product gross margin by an estimated 8-12 percentage points versus partner-led sales in 2024-and building its own market identity; expanding these internal teams is a strategic priority to increase independence as Genmab targets direct launches for 3-5 products by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScientific meetings are a primary channel for presenting Genmab's new clinical data and building awareness among oncology specialists; at ASCO and ASH Genmab reached ~8,000-12,000 attendees per major presentation in 2024, concentrating potential prescribers and partners. These forums also establish scientific credibility for antibody candidates-peer-reviewed abstracts and plenary talks contributed to a 15% increase in investigator-initiated trials for Genmab programs in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Healthcare Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab uses digital platforms to share medical info and education with HCPs and patients, via portals and webinars that explain mechanisms and safety; in 2024 Genmab logged ~120 global webinars and grew HCP portal users 35% year-over-year to ~18,000 users.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120 global webinars in 2024\u003c\/li\u003e\n\u003cli\u003e18,000 HCP portal users (up 35% YoY)\u003c\/li\u003e\n\u003cli\u003eDigital outreach supports global trials and safety updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePublishing pivotal clinical trial results in high-impact, peer-reviewed journals validates Genmab's data and directly influences physician prescribing; for example, Genmab's 2024 Janssen-partnered daratumumab combo trials reported a 42% improvement in progression-free survival (PFS) in Phase 3, bolstering uptake.\u003c\/p\u003e\n\u003cp\u003eSuccess in this channel strengthens Genmab's reputation in antibody oncology and supports commercial adoption, aiding payer coverage and helping justify R\u0026amp;D spend (2024 R\u0026amp;D expense: DKK 5.1bn).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublishes peer-reviewed Phase 3 results (e.g., 42% PFS gain)\u003c\/li\u003e\n\u003cli\u003eDrives physician adoption and payer decisions\u003c\/li\u003e\n\u003cli\u003eReinforces leadership in antibody R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eSupports commercial uptake and ROI on DKK 5.1bn R\u0026amp;D (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab scales hybrid commercial model: direct launches lift margins; strong HCP engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab sells via partner commercial forces (Janssen, AbbVie) and selective in-house teams; 2024 direct launches raised gross margins ~8-12 ppt, targeting 3-5 direct launches by 2028. Scientific meetings (ASCO\/ASH) reached ~8-12k attendees per major presentation; 120 webinars and 18k HCP portal users (up 35% YoY) support uptake; 2024 R\u0026amp;D spend DKK 5.1bn; Phase 3 daratumumab combo +42% PFS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003eJanssen\/AbbVie reach; avoids global sales build\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e+8-12 ppt margin; 3-5 launches by 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMeetings\u003c\/td\u003e\n\u003ctd\u003e8-12k attendees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e120 webinars; 18k HCPs (+35% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eDKK 5.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Corporations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge-cap pharmaceutical corporations license Genmab's antibody engineering and enter co-development deals to strengthen oncology pipelines; in 2024 Genmab reported cumulative partnership revenue exceeding €2.3 billion, driven by upfronts and milestone payments. These B2B partners supply steady long-term royalty streams-Genmab earned €620 million in royalties and product revenue in 2024-making this segment central to cash flow and R\u0026amp;D leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized oncologists, oncology nurses, and hospital systems-who prescribe and administer Genmab's antibodies-drive uptake; they demand peer‑reviewed clinical data, real‑world evidence, and practical protocols (e.g., 2024 trials showing 30-45% response rate in target indications) plus training and infusion support. Meeting these needs is critical for commercial success: provider adoption correlates with faster revenue ramp and lower time‑to‑peak sales for biologics (median 3-5 years post‑approval).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePublic and private payers-insurers and government programs like Medicare\/Medicaid-reimburse Genmab therapies and prioritize cost-effectiveness and clinical value versus existing treatments; in 2024 US Medicare drug spending hit $137B, so demonstrating superior outcomes and ICER (incremental cost-effectiveness ratio) below common thresholds (often $50k-$150k per QALY) is critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCancer Patient Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab's end-users are cancer patients-notably those with multiple myeloma and cervical cancer-seeking longer survival, better quality of life, and fewer complications; in 2024 Genmab-backed therapies reached an estimated 60,000 patients globally, driving revenue of DKK 18.5bn in 2024 that funds R\u0026amp;D toward unmet needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatients: multiple myeloma, cervical cancer, others\u003c\/li\u003e\n\u003cli\u003eNeeds: improved survival, QoL, fewer AEs\u003c\/li\u003e\n\u003cli\u003e2024 reach: ~60,000 patients worldwide\u003c\/li\u003e\n\u003cli\u003e2024 revenue: DKK 18.5bn funding R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic and non-profit research institutions collaborate with Genmab on early discovery and translational medicine, supplying foundational research that drives new therapeutic targets and enabling partnerships that reduced preclinical timelines by ~15% in recent collaborations (2024 internal data).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProvide basic science and target validation\u003c\/li\u003e\n\u003cli\u003eEnable translational programs leading to INDs\u003c\/li\u003e\n\u003cli\u003eLow direct revenue but high strategic value\u003c\/li\u003e\n\u003cli\u003eExamples: university labs, research hospitals, non-profit consortia\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab 2024: €2.3bn partner deals, €620m revenue, 60k patients, faster R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab serves big pharma partners (€2.3bn cumulative partnership revenue to 2024; €620m royalties\/product revenue in 2024), providers (drive uptake; 30-45% trial response rates), payers (US Medicare drug spend €≈130bn in 2024), patients (~60,000 reached; DKK 18.5bn 2024 revenue), and academia (cuts preclinical timelines ~15% in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric 2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003e€2.3bn cum.; €620m rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e~60,000; DKK 18.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eUS Medicare €≈130bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003e-15% timelines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab spends the largest share of its operating budget on R\u0026amp;D-DKK 5.0 billion in 2024 (48% of Opex), funding antibody discovery, platform upkeep, lab consumables, advanced equipment, and salaries for ~1,500 research staff; ongoing R\u0026amp;D is critical to sustain the pipeline and competitive lead.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRunning global, multi-center clinical trials forces Genmab to absorb high costs for patient recruitment, monitoring, and data analysis; Phase 3 programs can exceed $100-300M per trial and often span 3-7 years, increasing follow-up and site-management expenses. Genmab offsets much of this via partner cost-sharing-e.g., its Janssen collaboration has historically covered large portions-yet independent trials still represent multi-hundred‑million dollar capital commitments on the balance sheet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonnel and Talent Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePersonnel and Talent Management: Genmab spends heavily to attract and keep top scientific and management talent-R\u0026amp;D and SG\u0026amp;A payrolls drove ~€1.1bn of the €1.8bn operating expenses in 2024, reflecting competitive pay, benefits, and equity; training and development budgets (estimated 3-5% of payroll) fund ongoing scientific and regulatory upskilling to protect innovation and regulatory readiness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManufacturing complex biologics forces Genmab to fund specialized GMP facilities and outsourced CDMOs; in 2024 Genmab reported manufacturing and supply costs rising as part of R\u0026amp;D and COGS, reflecting higher production of clinical supply and commercial share for co-marketed drugs like daratumumab (market royalties and supply commitments scale with sales exceeding $1.5bn in recent years).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP facilities and CDMO fees\u003c\/li\u003e\n\u003cli\u003eClinical trial material production\u003c\/li\u003e\n\u003cli\u003eCommercial supply share for co-marketed products\u003c\/li\u003e\n\u003cli\u003eSupply-chain quality controls to avoid treatment disruptions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdministrative and Legal Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating globally, Genmab incurs substantial overhead for legal services, IP filings, and governance-Genmab reported DKK 1.1 billion (≈USD 160m) in R\u0026amp;D and admin-related costs in 2024, with legal\/IP a material slice given its antibody patent portfolio.\u003c\/p\u003e\n\u003cp\u003ePatent defense and cross-border tax\/trade compliance add recurring costs and risk mitigation needs, essential to protect assets and enable collaborations and licensing deals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 legal\/IP spend: material within DKK 1.1bn admin\/R\u0026amp;D costs\u003c\/li\u003e\n\u003cli\u003eGlobal patent portfolio: dozens of families across US\/EU\/JP\u003c\/li\u003e\n\u003cli\u003eCompliance adds recurring fees, litigation and tax advisory costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab pours into R\u0026amp;D: DKK5.0bn, Phase‑3 $100-300M each, payroll ≈DKK7.4bn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab's 2024 cost base centers on R\u0026amp;D: DKK 5.0bn (48% of Opex), clinical trials (Phase 3: $100-300M each), personnel (~DKK 7.4bn payroll-related across R\u0026amp;D\/SG\u0026amp;A ≈€1.1bn), and manufacturing\/CDMO plus legal\/IP (DKK 1.1bn admin\/R\u0026amp;D-related). Partner deals offset trial costs but independent programs remain multi‑hundred‑million commitments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 Cost\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eDKK 5.0bn (48% Opex)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trial (per Phase 3)\u003c\/td\u003e\n\u003ctd\u003e$100-300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayroll (R\u0026amp;D+SG\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003e≈DKK 7.4bn (≈€1.1bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal\/IP \u0026amp; admin\u003c\/td\u003e\n\u003ctd\u003eDKK 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties on Commercial Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab earns double-digit percentage royalties on net sales of partner‑marketed drugs, chiefly Darzalex with Janssen; royalties totaled about DKK 9.6 billion (≈USD 1.4 billion) in 2024, up ~5% year‑on‑year. This high‑margin, recurring revenue scales with global Darzalex sales and remains the main driver of Genmab's profitability and cash flow stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab earns one-time milestone payments when partners hit development, regulatory, or commercial triggers; these have ranged from low‑millions to \u0026gt;300 million USD for major approvals (for example, similar oncology deals saw regulatory milestones of ~100-300M in 2021-2024). These periodic cash infusions fund internal R\u0026amp;D and reduced dilution, with milestone receipts helping finance pipeline advancement and trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs Genmab shifts to co-promotion for select antibodies, it records direct product sales in markets where it co-commercializes, letting it capture margins beyond royalties; 2025 guidance projects product sales rising to ~DKK 3.2-3.6 billion as more independent pipeline assets launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology Licensing Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab earns licensing revenue by charging upfront and annual maintenance fees for access to platforms like DuoBody; in 2024 Genmab reported 1.1 billion DKK in collaboration and licensing income, driven largely by platform deals.\u003c\/p\u003e\n\u003cp\u003eLicensing lets Genmab monetize IP without funding development, providing steady, lower-risk cash flow and royalty upside if partners commercialize products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 collaboration\/licensing revenue: 1.1 billion DKK\u003c\/li\u003e\n\u003cli\u003eFee types: upfront payments + annual maintenance\u003c\/li\u003e\n\u003cli\u003ePlatform example: DuoBody antibody technology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab often secures collaborative research funding where partners reimburse research costs; in 2024 disclosed collaborations, cost-covering payments reduced Genmab's R\u0026amp;D cash outflow by an estimated €40-60m, keeping early-stage discovery cash-neutral.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners reimburse research costs, preserving Genmab staff capacity\u003c\/li\u003e\n\u003cli\u003e2024 estimate: €40-60m R\u0026amp;D cash relief\u003c\/li\u003e\n\u003cli\u003eOffsets early-stage expenses and lowers dilution risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab shifts revenue: DKK9.6bn royalties + DKK3.2-3.6bn product sales guidance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab's revenue mix: royalties (DKK 9.6bn in 2024, ~USD 1.4bn) from partner‑sold drugs-mainly Darzalex-plus collaboration\/licensing (DKK 1.1bn in 2024) and milestone payments (up to \u0026gt;USD 300m per major trigger historically); co‑promotion\/product sales expected ~DKK 3.2-3.6bn in 2025; 2024 partner cost reimbursements cut R\u0026amp;D cash outflow by ~€40-60m.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003e2025 guide\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003eDKK 9.6bn\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eDKK 1.1bn\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eDKK 3.2-3.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D relief\u003c\/td\u003e\n\u003ctd\u003e€40-60m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57346855207243,"sku":"genmab-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/genmab-canvas-business-model.webp?v=1779139221","url":"https:\/\/valuechainanalysis.com\/products\/genmab-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}